BALTIMORE--(BUSINESS WIRE)--ReGelTec, Inc., announced that Dr. Douglas Beall received the “Top Abstract Award” from the American Society of Pain and Neuroscience (ASPN) for his presentation of the 3-Year follow-up data on chronic low back pain patients treated with ReGelTec’s HYDRAFIL System. The presentation was given to a packed room of physicians at the 6th Annual meeting of ASPN in Miami, Florida. The HYDRAFIL System allows doctors to treat chronic low back pain due to degenerative disc disease with a hydrogel that can be melted and implanted into a patient’s disc using a needle. The hydrogel solidifies when it cools to body temperature providing cushioning, restoring the natural biomechanics of the disc, and filling cracks and fissures in annulus. The procedure is performed in an outpatient setting with only local anesthesia.
“I am honored that my colleagues from ASPN choose my Abstract reporting on the one, two, and three-year results obtained when treating patients with the HYDRAFIL System as the Top Abstract at the 6th Annual Meeting,” said Dr. Douglas Beall, Chief of Interventional Spine Services, Comprehensive Specialty Care, Edmond, Oklahoma. “The pain and functional improvements achieved with the HYDRAFIL System in patients with chronic low back pain due to degenerative disc disease are excellent and we cannot wait to start the FDA Pivotal Study later this year.”
“We are extremely excited about the clinical results seen to date in the first seventy-five patients treated with the HYDRAFIL System and having Dr. Beall’s presentation win the Top Abstract award is further validation of those results,” said Bill Niland, the company’s co-founder and CEO. “We believe that the HYDRAFIL System will transform the treatment of chronic low back pain due to degenerative disc disease so receiving this recognition from the interventional pain community is very rewarding and motivating.”
ABOUT REGELTEC, INC:
ReGelTec, Inc. is a clinical stage medical device company commercializing the HYDRAFIL® System, a percutaneous treatment for chronic low back pain due to degenerative disc disease. The company was formed when a team of chemical engineers with extensive experience in polymer science partnered with a cross-functional team of medical device professionals with multiple successful exits. The HYDRAFIL System contains a hydrogel that can be injected into a degenerated disc via a needle. Once approved, HYDRAFIL will offer patients suffering from chronic back pain due to degenerative disc disease a minimally invasive treatment option beyond traditional conservative care. The HYDRAFIL System is an investigational device, limited by United States law to investigational use.
